Trials Sponsors Conditions Drugs Pricing

Conditions

Menstrual Irregularities Hyperandrogenism

Keywords

PCOMetformin

Outcome Measures

Primary Outcomes (4)

HIRSUTISM
Hirsutism will be assessed by ferryman gallaway scoring (numerical/quantitative)
3 months
POLYCYSTIC OVARIES
assessment on ultrasound (qualitative-present/not present)
3 months
MENSTRUAL IRREGULARITIES
assessment on history(qualitative-present/not present)
3 months
BMI
weight and height will be combined to report BMI in kg/m2
3 months

Secondary Outcomes (4)

SERUM FASTING INSULIN
3 months
FASTING BLOOD SUGAR
3 months
FREE TESTOSTERONE
3 months
FREE ANDROGEN INDEX
3 months

Study Arms (2)

metformin

EXPERIMENTAL

TAB METFORMIN 500mg TDS

Drug: TAB METFORMIN

pioglitazone

EXPERIMENTAL

TAB PIOGLITAZONE 30 mg OD

Drug: TAB PIOGLITAZONE

Interventions

TAB METFORMINDrug

INSULIN SENSITIZING AGENTS

metformin

TAB PIOGLITAZONEDrug

INSULIN SENSITIZING AGENT

pioglitazone

Eligibility Criteria

Age18 Years - 40 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

women of age 18-40 with primary or secondary infertility.
Polycystic ovarian syndrome daignosed using rotterdam criteria.

Sponsors & Collaborators

Dow University of Health Sciences
Otherlead

Study Sites (1)

Dow University Hospital OJHA

Karachi, Sindh, 75270, Pakistan

RECRUITING

MeSH Terms

Conditions

Menstruation DisturbancesHyperandrogenism

Interventions

MetforminPioglitazone

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms46, XX Disorders of Sex DevelopmentDisorders of Sex DevelopmentUrogenital AbnormalitiesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesAdrenogenital Syndrome

Study Officials

Bader F Zuberi, FCPS
Dow University of Health Sciences
STUDY DIRECTOR

Central Study Contacts

Jahan A Ainuddin

CONTACT

03012530961 jahanaraainuddin@yahoo.com

Study Design

Study Type: interventional
Phase: phase 1 2
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

July 30, 2018

First Posted

November 29, 2018

Study Start

June 18, 2018

Actual (reported)

Primary Completion

December 17, 2018

Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (4)

Study Arms (2)

metformin

pioglitazone

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (4)

Study Arms (2)

metformin

pioglitazone

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations